This dataset is published in support of the article Guida, F. et al., "The blood metabolite of incident kidney cancer: A case-control study nested within the Metkid consortium", PLOS Medicine.
The dataset contains metabolite (Metabolon and Biocrates) genome-wide association study (GWAS) summary statistics for a selection of single nucleotide polymorphisms (SNPs). SNPs are those BMI-associated and dental disease-associated variants used in Mendelian randomization analyses investigating the association between BMI or dental disease and circulating metabolites.
The GWAS results for the 174 Biocrates metabolites reported here are from a fixed-effects meta-analysis combining results from the Fenland cohort (maximum N= 9736, available at: https://omicscience.org/apps/crossplatform/) with those from the EPIC-Norfolk (maximum N=5841) and INTERVAL studies (maximum N=40,818). The derivation of these data are described in: Lotta et al. 2021, Nature Genetics 53(1):54-64. DOI: 10.1038/s41588-020-00751-5.
The GWAS results for the 913 Metabolon metabolites reported here are from a meta-analysis combining results from the EPIC-Norfolk (N=5,841) and INTERVAL studies (N=8,455). The Metabolon GWAS meta-analysis results were shared pre-publication and will be made available via www.omicscience.org upon publication.
The GWAS data described were generated by:
Claudia Langenberg, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
Isobel D Stewart, MRC Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom
Adam Butterworth, British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
Praveen Surendran, British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
We request that any use of these data acknowledges the contribution of the above named researchers and cites (1) Lotta et al. 2021, Nature Genetics 53(1):54-64. DOI: 10.1038/s41588-020-00751-5; and (2) Guida, F. et al., "The blood metabolite of incident kidney cancer: A case-control study nested within the Metkid consortium", PLOS Medicine.